Welcome to our dedicated page for CRISPR Therapeutics news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics stock.
CRISPR Therapeutics AG (symbol: CRSP) is a pioneering gene editing company dedicated to the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary technology allows for precise, directed changes to genomic DNA, enabling the treatment of genetically defined diseases.
The company's portfolio spans a broad range of therapeutic programs, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. One of its notable achievements is the development and approval of Casgevy, a therapeutic targeting sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals.
To bolster its research and development, CRISPR Therapeutics has forged strategic partnerships with renowned companies such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. These collaborations aim to accelerate and expand the company's efforts in bringing novel therapies to market.
Headquartered in Zug, Switzerland, CRISPR Therapeutics operates through its wholly-owned U.S. subsidiary, with R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California, and London, United Kingdom.
The company's ongoing projects include advancing gene editing programs in immuno-oncology and developing stem cell-derived therapies for the treatment of Type 1 diabetes. With its innovative approach and strategic collaborations, CRISPR Therapeutics is at the forefront of the gene editing revolution, poised to make significant impacts in the field of medicine.
For more information, please visit www.crisprtx.com.
CRISPR Therapeutics (Nasdaq: CRSP) announced the presentation of preclinical data at the AACR 2023 Annual Meeting in Orlando, FL, scheduled for April 14-19, 2023. The presentation titled CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic CAR T cells highlights novel edits that enhance potency and efficacy for treating lymphoid and solid tumors.
This session will take place on April 16, 2023, from 1:25 to 1:40 p.m. ET at the Tangerine Ballroom 2. Data will be under embargo until the session starts, with a copy of the presentation available post-session on their official website.
CRISPR Therapeutics (Nasdaq: CRSP) has appointed Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. Dr. Prasad brings extensive experience from William Blair & Company, where he focused on cell and gene therapy sectors. He succeeds Brendan Smith, who is departing for new opportunities. Dr. Prasad's background includes leading biotechnology analysis and consulting for regulatory bodies. CEO Samarth Kulkarni highlighted Dr. Prasad's vital expertise and market relationships as significant assets for the company. CRISPR Therapeutics continues to advance its gene editing technologies and strategic partnerships, positioning itself within the biopharmaceutical landscape.
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on March 6, 2023, at 10:30 a.m. ET. This event highlights the company’s focus on transformative gene-based medicines for serious diseases.
A live webcast will be available on the company's Investors website, with an archived replay accessible for 14 days post-event. CRISPR Therapeutics utilizes its proprietary CRISPR/Cas9 platform to develop treatments across various disease areas, including oncology and rare diseases, in collaboration with leading partners.
CRISPR Therapeutics (CRSP) reported significant advancements in its product pipeline, including completed regulatory submissions for exa-cel for transfusion-dependent beta thalassemia and sickle cell disease in Europe, with a U.S. BLA submission expected by Q1 2023. The company is also advancing clinical trials for CAR T therapies CTX110 and CTX130, along with new candidates CTX112 and CTX131. Financially, CRISPR ended 2022 with $1.87 billion in cash but reported a net loss of $650.2 million for the year, marking a significant contrast to the $377.7 million net income in 2021.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two upcoming investor conferences in February 2023. The SVB Securities Global Biopharma Conference will take place on February 15, 2023, at 1:40 p.m. ET, followed by Citi’s 2023 Virtual Oncology Leadership Summit on February 22, 2023, at 1:00 p.m. ET. These sessions will feature live webcasts available on the company's website with replays accessible for 14 days post-event. CRISPR Therapeutics focuses on developing gene-based medicines for serious diseases using the CRISPR/Cas9 platform, establishing partnerships with companies like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) announced that its senior management will participate in B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 10:30 a.m. ET. The event will showcase the company's commitment to developing transformative gene-based therapies for serious diseases using its proprietary CRISPR/Cas9 platform. Interested parties can register for a live webcast or replay on the company's website under the 'Events & Presentations' section.
CRISPR Therapeutics (Nasdaq: CRSP) has appointed Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding has significant experience in biopharma, previously serving at Remix Therapeutics, where he was pivotal in raising over $150M and forming strategic collaborations. His expertise is expected to support CRISPR's growth and enhance its business development operations, as stated by CEO Samarth Kulkarni. CRISPR focuses on gene-based therapies utilizing its CRISPR/Cas9 platform for serious diseases.
CRISPR Therapeutics has provided an update from its Phase 1 CARBON trial for CTX110, a CAR T cell therapy targeting CD19+ B-cell malignancies. At the recent ASH Annual Meeting, data confirmed that CTX110 can lead to long-term complete remissions in heavily pre-treated Large B-cell Lymphoma patients, with three patients maintaining remission for over two years. The trial suggests a positive safety profile and beneficial effects of consolidation dosing, prompting the initiation of a Phase 2 registrational trial in collaboration with regulatory agencies.
Vertex Pharmaceuticals and CRISPR Therapeutics announced upcoming oral presentations of clinical data for exagamglogene autotemcel (exa-cel) at the 2022 ASH Annual Meeting. This investigational therapy targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Key presentations include efficacy and safety data from Phase 3 trials, with plans for regulatory submissions in the U.S., U.K., and EU by early 2023. The studies highlight the quality of life impacts for patients undergoing treatment.
FAQ
What is the current stock price of CRISPR Therapeutics (CRSP)?
What is the market cap of CRISPR Therapeutics (CRSP)?
What is CRISPR Therapeutics AG?
What does the CRISPR/Cas9 platform do?
Where is CRISPR Therapeutics headquartered?
What is Casgevy?
What types of diseases is CRISPR Therapeutics targeting?
Who are CRISPR Therapeutics' key partners?
What are some of CRISPR Therapeutics' current projects?
Where are CRISPR Therapeutics' R&D operations based?
How has CRISPR Therapeutics impacted the field of medicine?
Where can I find more information about CRISPR Therapeutics?
